Home > Boards > US OTC > Delisted > Aralez Pharmaceuticals Inc. (fka ARLZQ)

<u>$ARLZQ: NEWS... Intercept acquires Bezafibrate from Aralez-Pharma</u>

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
makinezmoney Member Profile
Followed By 571
Posts 14,211
Boards Moderated 6
Alias Born 12/10/12
160x600 placeholder
makinezmoney   Monday, 01/07/19 07:41:14 AM
Re: None
Post # of 470 
$ARLZQ: NEWS... Intercept acquires Bezafibrate from Aralez-Pharma

Major HealthCare conference happening this week.....

37th Annual J.P. Morgan Healthcare Conference


In addition, Intercept announced that it has acquired from Aralez Pharmaceuticals Inc. its license to develop and commercialize bezafibrate in the U.S., its IND on file with the FDA and other associated regulatory documentation, and a non-exclusive license to certain of Aralez’s intellectual property. Bezafibrate, a pan-peroxisome proliferator-activated receptor (PPAR) agonist that has been studied in PBC, is not approved in the U.S. for any indication. Intercept intends to initiate a Phase 2 study to evaluate the efficacy, safety and tolerability of bezafibrate in combination with OCA in patients with PBC, with the longer term goal to develop and seek regulatory approval for a fixed dose combination regimen in this indication and potentially other liver diseases.

“We are pleased to have acquired the U.S. rights to bezafibrate and look forward to studying it in combination with OCA as a potential treatment for progressive non-viral liver diseases. Based on the potential benefits of combining bezafibrate with OCA in PBC, we will initially study the combination in this indication,” said Christian Weyer, M.D., M.A.S., Intercept's Executive Vice President, Research & Development.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist